Financial Ratios Medacta Group SA
Equities
MOVE
CH0468525222
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.60 CHF | +0.95% |
|
-3.38% | -4.99% |
| Feb. 03 | Medacta Group SA, 2025 Sales/ Trading Statement Call, Feb 03, 2026 | |
| Feb. 03 | Medacta Group Posts Higher Preliminary FY25 Revenue | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | 7.73 | 9.13 | 8.09 | 7.47 | 7.81 | ||||
Return on Total Capital | 11.17 | 12.56 | 10.74 | 9.75 | 10.04 | ||||
Return On Equity % | 25.76 | 26.35 | 18.46 | 15.66 | 20.54 | ||||
Return on Common Equity | 25.76 | 26.35 | 18.46 | 15.66 | 20.54 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 70.83 | 71.94 | 69.83 | 68.1 | 67.64 | ||||
SG&A Margin | 51.33 | 50.53 | 50.38 | 49.43 | 48.45 | ||||
EBITDA Margin % | 27.09 | 27.18 | 24.47 | 23.42 | 24.08 | ||||
EBITA Margin % | 18.56 | 19.58 | 16.63 | 15.61 | 16.29 | ||||
EBIT Margin % | 17.47 | 18.72 | 15.89 | 14.98 | 15.74 | ||||
Income From Continuing Operations Margin % | 12.26 | 14.19 | 10.58 | 9.27 | 12.34 | ||||
Net Income Margin % | 12.26 | 14.19 | 10.58 | 9.27 | 12.34 | ||||
Net Avail. For Common Margin % | 12.26 | 14.19 | 10.58 | 9.27 | 12.34 | ||||
Normalized Net Income Margin | 8.95 | 11.13 | 8.98 | 7.44 | 9.51 | ||||
Levered Free Cash Flow Margin | 8.98 | -5.09 | -1.78 | -6.88 | -2.68 | ||||
Unlevered Free Cash Flow Margin | 9.61 | -4.5 | -1.25 | -6.04 | -1.89 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.71 | 0.78 | 0.81 | 0.8 | 0.79 | ||||
Fixed Assets Turnover | 1.95 | 2.18 | 2.2 | 2.1 | 2.02 | ||||
Receivables Turnover (Average Receivables) | 6.45 | 6.9 | 6.36 | 5.92 | 5.82 | ||||
Inventory Turnover (Average Inventory) | 0.82 | 0.81 | 0.89 | 0.87 | 0.85 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 1.5 | 1.67 | 3.18 | 2.33 | 2.51 | ||||
Quick Ratio | 0.69 | 0.64 | 1.32 | 0.82 | 0.95 | ||||
Operating Cash Flow to Current Liabilities | 0.41 | 0.4 | 0.83 | 0.5 | 0.68 | ||||
Days Sales Outstanding (Average Receivables) | 56.77 | 52.88 | 57.36 | 61.67 | 62.85 | ||||
Days Outstanding Inventory (Average Inventory) | 447.61 | 448.33 | 410.2 | 419.17 | 429.24 | ||||
Average Days Payable Outstanding | 62.32 | 62.55 | 63.65 | 56.74 | 64.2 | ||||
Cash Conversion Cycle (Average Days) | 442.06 | 438.66 | 403.92 | 424.1 | 427.89 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 91.32 | 59.73 | 62.78 | 61.74 | 64.23 | ||||
Total Debt / Total Capital | 47.73 | 37.39 | 38.57 | 38.17 | 39.11 | ||||
LT Debt/Equity | 47.77 | 28.72 | 57.88 | 44.91 | 48.13 | ||||
Long-Term Debt / Total Capital | 24.97 | 17.98 | 35.56 | 27.77 | 29.3 | ||||
Total Liabilities / Total Assets | 62.73 | 53.73 | 53.01 | 52.57 | 52.07 | ||||
EBIT / Interest Expense | 17.36 | 19.75 | 18.96 | 11.2 | 12.37 | ||||
EBITDA / Interest Expense | 28.46 | 30 | 30.74 | 18.5 | 19.96 | ||||
(EBITDA - Capex) / Interest Expense | 19.5 | 16.49 | 14.79 | 8.3 | 8.08 | ||||
Total Debt / EBITDA | 1.74 | 1.31 | 1.53 | 1.61 | 1.63 | ||||
Net Debt / EBITDA | 1.18 | 1.11 | 1.24 | 1.45 | 1.42 | ||||
Total Debt / (EBITDA - Capex) | 2.53 | 2.38 | 3.18 | 3.59 | 4.02 | ||||
Net Debt / (EBITDA - Capex) | 1.72 | 2.02 | 2.59 | 3.23 | 3.5 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | -2.62 | 20.04 | 20.38 | 16.85 | 15.62 | ||||
Gross Profit, 1 Yr. Growth % | -4.22 | 21.93 | 16.85 | 13.95 | 14.83 | ||||
EBITDA, 1 Yr. Growth % | 23.24 | 20.45 | 9.35 | 11.86 | 18.84 | ||||
EBITA, 1 Yr. Growth % | 29.7 | 26.66 | 3.52 | 9.68 | 20.67 | ||||
EBIT, 1 Yr. Growth % | 31.79 | 28.65 | 3.54 | 10.16 | 21.47 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 212.77 | 38.9 | -10.23 | 2.41 | 53.89 | ||||
Net Income, 1 Yr. Growth % | 212.77 | 38.9 | -10.23 | 2.41 | 53.89 | ||||
Normalized Net Income, 1 Yr. Growth % | 27.02 | 49.21 | -1.52 | -3.17 | 47.83 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | 212.77 | 39.27 | -10.34 | 2.6 | 54.01 | ||||
Accounts Receivable, 1 Yr. Growth % | -4.72 | 29.82 | 31.16 | 21.41 | 14.28 | ||||
Inventory, 1 Yr. Growth % | 12.35 | 19.18 | 17.79 | 33.45 | 9.58 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | -2.6 | 17.2 | 21.56 | 22.35 | 18.76 | ||||
Total Assets, 1 Yr. Growth % | 7.12 | 10.71 | 19.46 | 19.06 | 13.84 | ||||
Tangible Book Value, 1 Yr. Growth % | 40.88 | 42.27 | 23.75 | 21.61 | 15.87 | ||||
Common Equity, 1 Yr. Growth % | 33.66 | 37.45 | 21.32 | 20.16 | 15.04 | ||||
Cash From Operations, 1 Yr. Growth % | 39.77 | -9.28 | 35.98 | 2.2 | 42.61 | ||||
Capital Expenditures, 1 Yr. Growth % | -34.21 | 70.39 | 25.63 | 19.26 | 28.15 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | -366.81 | -168.05 | -59.24 | 352.4 | -54.86 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -459.68 | -156.2 | -67.6 | 463.62 | -63.84 | ||||
Dividend Per Share, 1 Yr. Growth % | - | - | 5.89 | 8.14 | 24.46 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 5.34 | 8.12 | 20.21 | 18.6 | 16.24 | ||||
Gross Profit, 2 Yr. CAGR % | 2.49 | 8.07 | 19.36 | 15.39 | 14.39 | ||||
EBITDA, 2 Yr. CAGR % | -1.64 | 21.84 | 14.24 | 10.6 | 15.3 | ||||
EBITA, 2 Yr. CAGR % | -6.68 | 28.17 | 13.78 | 6.56 | 15.04 | ||||
EBIT, 2 Yr. CAGR % | -7.45 | 30.21 | 14.65 | 6.8 | 15.67 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -9.96 | 108.43 | 11.66 | -4.12 | 25.54 | ||||
Net Income, 2 Yr. CAGR % | -9.96 | 108.43 | 11.66 | -4.12 | 25.54 | ||||
Normalized Net Income, 2 Yr. CAGR % | -13.73 | 37.67 | 20.37 | -2.35 | 19.64 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -9.96 | 108.45 | 11.74 | -4.09 | 25.7 | ||||
Accounts Receivable, 2 Yr. CAGR % | 1.9 | 11.22 | 30.49 | 26.19 | 17.79 | ||||
Inventory, 2 Yr. CAGR % | 13.12 | 15.72 | 18.48 | 25.38 | 20.93 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.42 | 6.85 | 19.36 | 21.95 | 20.55 | ||||
Total Assets, 2 Yr. CAGR % | 9.95 | 8.9 | 15 | 19.26 | 16.42 | ||||
Tangible Book Value, 2 Yr. CAGR % | 45.4 | 41.57 | 32.69 | 22.68 | 18.7 | ||||
Common Equity, 2 Yr. CAGR % | 35.99 | 35.54 | 29.13 | 20.74 | 17.57 | ||||
Cash From Operations, 2 Yr. CAGR % | -5.27 | 12.61 | 11.07 | 17.88 | 20.73 | ||||
Capital Expenditures, 2 Yr. CAGR % | -22.26 | 5.88 | 46.31 | 22.4 | 23.63 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 87.91 | 34.75 | -46.53 | 35.8 | 42.9 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 113.45 | 42.17 | -56.6 | 35.14 | 42.77 | ||||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | 7.01 | 16.01 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 7.33 | 10.03 | 12.06 | 19.08 | 17.6 | ||||
Gross Profit, 3 Yr. CAGR % | 5.47 | 8.6 | 10.92 | 17.53 | 15.2 | ||||
EBITDA, 3 Yr. CAGR % | 4.55 | 5.23 | 17.17 | 13.44 | 13.28 | ||||
EBITA, 3 Yr. CAGR % | 2.02 | 3.32 | 18.85 | 12.39 | 11.07 | ||||
EBIT, 3 Yr. CAGR % | 1.58 | 3.29 | 20.1 | 13.13 | 11.48 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 3.46 | 4.04 | 57.4 | 8.49 | 12.26 | ||||
Net Income, 3 Yr. CAGR % | 3.46 | 4.04 | 57.4 | 8.49 | 12.26 | ||||
Normalized Net Income, 3 Yr. CAGR % | -3.42 | 3.56 | 22.55 | 11.95 | 12.13 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -86.96 | 4.04 | 57.35 | 8.61 | 12.31 | ||||
Accounts Receivable, 3 Yr. CAGR % | 7.46 | 10.47 | 17.51 | 27.39 | 22.09 | ||||
Inventory, 3 Yr. CAGR % | 16.34 | 15.11 | 16.4 | 23.28 | 19.87 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 14.74 | 10.59 | 11.54 | 20.35 | 20.88 | ||||
Total Assets, 3 Yr. CAGR % | 13.81 | 10.2 | 12.31 | 16.34 | 17.42 | ||||
Tangible Book Value, 3 Yr. CAGR % | 20.79 | 44.35 | 35.36 | 28.89 | 20.36 | ||||
Common Equity, 3 Yr. CAGR % | 17.45 | 36.47 | 30.62 | 26.07 | 18.81 | ||||
Cash From Operations, 3 Yr. CAGR % | 4.93 | -6.63 | 19.91 | 8.03 | 25.61 | ||||
Capital Expenditures, 3 Yr. CAGR % | -3.46 | 0.98 | 12.09 | 36.67 | 24.29 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 13.57 | 33.94 | -8.63 | 8.95 | -5.93 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.04 | 36.8 | -12.17 | 2.02 | -12.91 | ||||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | - | 12.54 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 10.64 | 12.31 | 13.38 | 13.71 | ||||
Gross Profit, 5 Yr. CAGR % | - | 9.69 | 10.82 | 11.27 | 12.29 | ||||
EBITDA, 5 Yr. CAGR % | - | 7.9 | 8.33 | 7.15 | 16.42 | ||||
EBITA, 5 Yr. CAGR % | - | 6.78 | 6.57 | 4.34 | 17.32 | ||||
EBIT, 5 Yr. CAGR % | - | 6.36 | 6.62 | 4.4 | 18.31 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 5.61 | 6.66 | 0.69 | 43.79 | ||||
Net Income, 5 Yr. CAGR % | - | 5.61 | 6.66 | 0.69 | 43.79 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 5.68 | 5.47 | 0.87 | 21.38 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | -69.53 | -69.23 | 0.71 | 43.83 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 10.5 | 16.14 | 16.51 | 17.62 | ||||
Inventory, 5 Yr. CAGR % | - | 15.1 | 17.2 | 19.11 | 18.19 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 12.25 | 16.57 | 15 | 15.06 | ||||
Total Assets, 5 Yr. CAGR % | - | 12.65 | 14.28 | 13.74 | 13.94 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 8.13 | 25.42 | 35.25 | 28.44 | ||||
Common Equity, 5 Yr. CAGR % | - | 9.04 | 21.99 | 29.95 | 25.24 | ||||
Cash From Operations, 5 Yr. CAGR % | - | -0.81 | 7.34 | 2.5 | 20.24 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 16.98 | 14.01 | 9.06 | 16.57 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | -15.98 | 35.49 | 9.27 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | -22.51 | 37.06 | 6.67 |
- Stock Market
- Equities
- MOVE Stock
- Financials Medacta Group SA
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















